BRPI0909183A2 - Composto, composição farmacêutica e método de tratamento de condição que responde a inibidor de estearoil-coa dessaturase - Google Patents

Composto, composição farmacêutica e método de tratamento de condição que responde a inibidor de estearoil-coa dessaturase

Info

Publication number
BRPI0909183A2
BRPI0909183A2 BRPI0909183-1A BRPI0909183A BRPI0909183A2 BR PI0909183 A2 BRPI0909183 A2 BR PI0909183A2 BR PI0909183 A BRPI0909183 A BR PI0909183A BR PI0909183 A2 BRPI0909183 A2 BR PI0909183A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
treatment method
coa desaturase
condition treatment
Prior art date
Application number
BRPI0909183-1A
Other languages
English (en)
Inventor
Alexander Bischoff
Kumar Sundaresan
Bala P Koteswara Rao
Bharathiraja Ainan
Hariharasubramanian Ayyamperumal
A R Girish
Srinivas Tatiparthy
Ganesh Prabhu
Hosahalli Subramanya
Original Assignee
Forest Lab Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forest Lab Holdings Ltd filed Critical Forest Lab Holdings Ltd
Publication of BRPI0909183A2 publication Critical patent/BRPI0909183A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BRPI0909183-1A 2008-03-20 2009-03-20 Composto, composição farmacêutica e método de tratamento de condição que responde a inibidor de estearoil-coa dessaturase BRPI0909183A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN575KO2008 2008-03-20
US4948008P 2008-05-01 2008-05-01
PCT/US2009/037835 WO2009117676A2 (en) 2008-03-20 2009-03-20 Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase

Publications (1)

Publication Number Publication Date
BRPI0909183A2 true BRPI0909183A2 (pt) 2015-08-25

Family

ID=41089526

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909183-1A BRPI0909183A2 (pt) 2008-03-20 2009-03-20 Composto, composição farmacêutica e método de tratamento de condição que responde a inibidor de estearoil-coa dessaturase

Country Status (14)

Country Link
US (1) US8129376B2 (pt)
EP (1) EP2268143A4 (pt)
JP (1) JP2011518774A (pt)
KR (1) KR20100134680A (pt)
CN (1) CN102036558A (pt)
AU (1) AU2009225441B2 (pt)
BR (1) BRPI0909183A2 (pt)
CA (1) CA2719000A1 (pt)
IL (1) IL208232A0 (pt)
MX (1) MX2010010241A (pt)
NZ (1) NZ588633A (pt)
RU (1) RU2010142937A (pt)
WO (1) WO2009117676A2 (pt)
ZA (1) ZA201007252B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2202223B1 (en) * 2007-10-18 2017-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound as blood rbp4 lowering agent
US8642583B2 (en) 2008-10-30 2014-02-04 Janssen Pharmaceutica Nv Serotonin receptor modulators
KR20120117905A (ko) 2010-01-28 2012-10-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 프로테아좀 활성을 향상시키는 조성물 및 방법
EP2593447B1 (de) 2010-07-15 2016-08-17 Bayer Intellectual Property GmbH 3-pyridyl-heteroarylcarboxamidverbindungen als schädlingsbekämpfungsmittel
TR201906779T4 (tr) 2011-05-12 2019-05-21 Proteostasis Therapeutics Inc Proteostaz regülatörleri.
NO2686520T3 (pt) * 2011-06-06 2018-03-17
FR3000491B1 (fr) * 2012-09-27 2015-08-28 Univ Lille Ii Droit & Sante Composes utilisables dans le traitement des infections mycobacteriennes
CN103772267A (zh) * 2012-10-24 2014-05-07 常州化学研究所 一种二苯胺制备咔唑的方法
WO2014116228A1 (en) 2013-01-25 2014-07-31 President And Fellows Of Harvard College Usp14 inhibitors for treating or preventing viral infections
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
UA118034C2 (uk) * 2013-11-14 2018-11-12 Елі Ліллі Енд Компані Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази
KR20160133004A (ko) 2014-04-04 2016-11-21 엑스-알엑스, 인크. 오토탁신의 치환된 스피로시클릭 억제제
CN107205972A (zh) * 2014-04-23 2017-09-26 X-Rx股份有限公司 自分泌运动因子的取代的n‑(2‑(氨基)‑2‑氧代乙基)苯甲酰胺抑制剂及它们的制备和在治疗lpa‑依赖的或lpa‑介导的疾病中的用途
US20160047307A1 (en) * 2014-08-15 2016-02-18 General Electric Company Power train architectures with low-loss lubricant bearings and low-density materials
WO2016054560A1 (en) 2014-10-02 2016-04-07 Flatley Discovery Lab Isoxazole compounds and methods for the treatment of cystic fibrosis
CN106432232A (zh) * 2016-09-18 2017-02-22 苏州汉德创宏生化科技有限公司 1‑哌啶‑4‑基‑1,3‑二氢‑咪唑[4,5‑b]吡啶‑2‑酮的合成方法
JP7278945B2 (ja) 2016-09-20 2023-05-22 サントル レオン ベラール 抗癌剤としてのベンゾイミダゾール誘導体
EP3529245A4 (en) 2016-10-24 2020-12-23 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THE LATEST
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
MA47212A (fr) 2017-01-06 2019-11-13 Yumanity Therapeutics Inc Méthodes de traitement de troubles neurologiques
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
CN107663184A (zh) * 2017-11-15 2018-02-06 上海皓伯化工科技有限公司 一种N‑Boc‑4‑羟基哌啶的合成方法
ES3043183T3 (en) 2018-03-23 2025-11-25 Janssen Pharmaceutica Nv Compounds and uses thereof
CN112566636A (zh) 2018-04-25 2021-03-26 优曼尼蒂治疗公司 化合物及其用途
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
MA54829A (fr) 2019-01-24 2021-12-01 Yumanity Therapeutics Inc Composés et leurs utilisations
US20220348563A1 (en) * 2019-09-13 2022-11-03 Dana-Farber Cancer Institute, Inc. Kdm inhibitors and uses thereof
CN110845396B (zh) * 2019-11-07 2023-01-20 宿迁联盛科技股份有限公司 一种2,2,6,6-四甲基-4-哌啶胺类化合物的制备方法
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
US12612367B2 (en) 2019-12-10 2026-04-28 Akebia Therapeutics, Inc. Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
CN117247347A (zh) * 2023-09-15 2023-12-19 安徽昊帆生物有限公司 N-Boc-4-氨基哌啶的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6659090A (en) 1989-11-16 1991-06-13 Warner-Lambert Company Acat inhibitors
US5459151A (en) * 1993-04-30 1995-10-17 American Home Products Corporation N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents
KR100477070B1 (ko) * 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
EP1315831B8 (en) 2000-02-24 2010-09-01 Xenon Pharmaceuticals Inc. Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
EP1322767B1 (en) 2000-09-26 2008-07-23 Xenon Pharmaceuticals Inc. Methods and compositions employing a stearoyl-coa desaturase-hscd5
JP2006518368A (ja) * 2003-02-21 2006-08-10 ファイザー・インク プロテインキナーゼ阻害剤としてのn−ヘテロシクリル置換アミノチアゾール誘導体
KR20050045927A (ko) * 2003-11-12 2005-05-17 주식회사 엘지생명과학 멜라노코틴 수용체의 항진제
JP4787529B2 (ja) * 2004-04-09 2011-10-05 大塚製薬株式会社 医薬組成物
US7951805B2 (en) * 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
JP4958787B2 (ja) * 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−CoAデサチュラーゼを阻害するためのピリジン誘導体
EP2316458A1 (en) * 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
US7842696B2 (en) * 2007-06-21 2010-11-30 Forest Laboratories Holdings Limited Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
KR20100125316A (ko) * 2008-03-26 2010-11-30 다이이찌 산쿄 가부시키가이샤 하이드록시퀴녹살린카르복사마이드 유도체

Also Published As

Publication number Publication date
WO2009117676A2 (en) 2009-09-24
RU2010142937A (ru) 2012-04-27
ZA201007252B (en) 2011-12-28
US20090239810A1 (en) 2009-09-24
MX2010010241A (es) 2010-12-06
US8129376B2 (en) 2012-03-06
WO2009117676A3 (en) 2010-01-07
AU2009225441B2 (en) 2012-12-13
CN102036558A (zh) 2011-04-27
EP2268143A4 (en) 2012-06-27
KR20100134680A (ko) 2010-12-23
CA2719000A1 (en) 2009-09-24
JP2011518774A (ja) 2011-06-30
NZ588633A (en) 2012-03-30
AU2009225441A1 (en) 2009-09-24
EP2268143A2 (en) 2011-01-05
IL208232A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
BRPI0817897A2 (pt) composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac
BRPI0920284A2 (pt) composição e método
EP2315220A4 (en) REACTOR COMPONENT AND REACTOR
BRPI0919575A2 (pt) método, e, composição
BRPI0911981A2 (pt) arquitetura de navegador de multiprocessos
BRPI0914770A2 (pt) anotação de conteúdo de página da web
BRPI0923011A2 (pt) método, e, produto de programa de computador
PT1976506T (pt) Extratos de plantas que contêm canabinoides como agentes neuroprotetores
EP2456310A4 (en) SUBSTITUTED BENZOIMIDAZOLSULFONAMIDES AND SUBSTITUTED INDOLSULFONAMIDES AS MGLUR4 POTENTIATORS
CL2012003646A1 (es) Composicion de control de fitoenfermedades que comprende un compuesto de carboxamida; metodo de control de fitoenfermedades.
BRPI0823277A2 (pt) Composição, e , método
BRPI0822472A2 (pt) Método, camundongo, e, composição
BRPI1015030A2 (pt) método de redução do conteúdo de compostos orgânicos voláteis solúveis em água presentes em um gás
EP2463316A4 (en) acrylate composition
FI20070935L (fi) Koostumus ja menetelmä puun käsittelemiseksi
FI20085564L (fi) Menetelmä puun suojaamiseksi
BRPI0823238A2 (pt) Composição, e, método
FR2942407B1 (fr) Procede de photomaquillage et composition de photomaquillage
IL213228A (en) Cutting fluid composition for wiresawing and a method of using same
BRPI0822782A2 (pt) composição farmacêutica que compreende rosuvastatina
FI20060484L (fi) Lannoiterae ja menetelmä sen valmistamiseksi
BRPI0913511A2 (pt) método, arranjo e produto de programa de computador para determinar um estado de uma caixa de engrenagem"
EP2132251A4 (en) COMPOSITION AND METHOD
DK2331310T3 (da) Imprægneringsanlæg og -fremgangsmåde
BRPI0910262A2 (pt) composição que compreende polióis

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DAS PRIORIDADES IN 575/KOL/2008 DE 20/03/2008 E US 61/049,480 DE 01/05/2008, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O E NO ART. 28 DO ATO NORMATIVO 128/1997, POR NAO ATENDEREM AO DISPOSTO NO ART. 27 DO ATO NORMATIVO 128/1997, POIS NAO FOI APRESENTADA CESSAO DAS REFERIDAS PRIORIDADES, QUE POSSUEM DEPOSITANTES DIFERENTES DO DEPOSITANTE DA FASE NACIONAL.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: NAO CONHECIDA A PETICAO NO 020130064868 DE 24/07/2013, EM VIRTUDE DO DISPOSTO NO ARTIGO 219 INCISO II DA LPI NO 9.279/96, UMA VEZ QUE NAO TEM FUNDAMENTACAO LEGAL.